下腔静脉滤器血栓形成的当代发生率与危险因素
基于VQI国际数据库2013–2019年数据,分析5780例有2年随访的下腔静脉滤器置入病例,滤器血栓形成发生率为1.3%。多变量分析显示随访中新发或进展性深静脉血栓、随访未用抗血小板治疗、颈内静脉入路、入院时静脉血栓栓塞症及临时滤器是独立预测因素。
要点
- 当代下腔静脉滤器血栓形成率较低,为1.3%。
- 随访中新发或进展性深静脉血栓是最强预测因素(HR 16.3)。
- 随访未用抗血小板治疗与滤器血栓风险升高独立相关(HR 4.8)。
核心结论
- 当代国际数据库中下腔静脉滤器血栓形成率仍较低,为1.3%。
- 超过5000例滤器置入患者的结果提示,置入滤器后应给予抗血小板治疗以降低滤器血栓风险。
研究设计与样本
- 回顾性队列研究,数据来自国际VQI数据库2013至2019年。
- 共62个美国和加拿大VQI参与中心,12,874例滤器置入,其中5780例有2年随访数据。
- 采用Kaplan-Meier生存曲线、log-rank检验、t检验或Mann-Whitney U检验及Cox回归分析。
- 另对入院时静脉血栓栓塞症患者进行亚组分析。
主要发现
- 5780例有2年随访的病例中,78例(1.3%)发生滤器血栓形成。
- 发生滤器血栓者糖尿病、冠状动脉疾病、术前抗血小板药物、术前他汀使用及出院和随访抗血小板药物比例显著更低。
- 单变量分析中,滤器血栓组入院时肺栓塞和静脉血栓栓塞症、颈内静脉入路(对比股静脉入路)、临时滤器、随访抗凝、随访滤器并发症、随访入路部位血栓、随访新发或进展性深静脉血栓比例更高,术后住院时间更长。
- 入院时静脉血栓栓塞症亚组中,多变量模型识别出相似预测因素,大面积肺栓塞也预测滤器血栓形成。
临床怎么用
- 下腔静脉滤器置入后应考虑给予抗血小板治疗以降低滤器血栓风险。
- 对随访中新发或进展性深静脉血栓、未用抗血小板治疗、颈内静脉入路、入院时静脉血栓栓塞症及临时滤器患者应加强滤器血栓监测。
局限性
- 仅纳入有2年随访数据的5780例,可能存在选择偏倚。
- 回顾性数据库研究,未报告多变量模型具体调整变量及模型效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Inferior vena cava (IVC) thrombosis is an uncommon complication associated with IVC filters (IVCFs), with studies reporting rates ranging from 1% to 31%. Few observational studies have described the risk factors associated with IVCF thrombosis, despite the significant clinical sequelae such as post-thrombotic syndrome, venous claudication, and venous ulceration. To better describe IVCF thrombosis and the risk factors, data were queried from Vascular Quality Initiative (VQI) participating centers. METHODS: IVCF data were obtained from the international VQI database from 2013 to 2019. The patients included in the present analysis had 2 years of follow-up data available. The baseline demographics, medical comorbidities, medication, and procedural, anatomic, and postoperative variables were assessed using Kaplan-Meier survival curves with log-rank tests, Student's t tests, or Mann-Whitney U tests for IVCF thrombosis at 2 years. Cox regression analyses were used to identify independent predictors of IVCF thrombosis. A subgroup analysis of those who had presented with venous thromboembolism (VTE) was also performed. RESULTS: A total of 62 U.S. and Canadian VQI-participating centers included 12,874 cases of IVCF placement. Of the 5780 cases with 2 years of follow-up available, 78 (1.3%) had developed IVCF thrombosis. Those who had experienced IVCF thrombosis had had significantly lower rates of diabetes, coronary artery disease, preoperative antiplatelet medications, preoperative statin use, and lower rates of discharge and follow-up antiplatelet medications. On univariable analysis, the cases of IVCF thrombosis also had higher rates of pulmonary embolism and VTE on admission, internal jugular venous access (vs femoral vein access), temporary IVCF use, follow-up anticoagulation, follow-up IVCF complication, follow-up access site thrombosis, and rates of new or propagated deep vein thrombosis at follow-up, and longer postoperative hospital stays. Multivariable analysis demonstrated that the independent predictors of IVCF thrombosis included new or propagated deep vein thrombosis at follow-up (hazard ratio [HR], 16.3; 95% confident interval [CI], 9.8-27.3; P < .001), no antiplatelet therapy at follow-up (HR, 4.8; 95% CI, 1.9-12.5; P = .001), internal jugular venous access (HR, 2.2; 95% CI, 1.4-3.5; P = .001), the presence of VTE on admission (HR, 2.7; 95% CI, 1.4-5.1; P = .002), and temporary IVCF placement (HR, 2.5; 95% CI, 1.1-5.6; P = .031). In an analysis of the subgroup of patients with VTE on admission, similar predictive factors were identified in a multivariable model. Massive pulmonary embolism was also predictive of IVCF thrombosis in this subgroup. CONCLUSIONS: The rate of IVCF thrombosis remained low in a contemporary international database. The results from the present study of >5000 patients with IVCFs suggest that antiplatelet therapy should be administered after IVCF placement to decreased the risk of IVCF thrombosis.
引用
- King RW, Wooster MD, Veeraswamy RK, et al. Contemporary rates of inferior vena cava filter thrombosis and risk factors. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 34425266. doi:10.1016/j.jvsv.2021.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。